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Cancer during pregnancy is occurring more often than in the past, and it is estimated that cancer
is diagnosed in approximately 1/1000 pregnancies. A consensus exists that management of these
patients should prioritize survival of the mother and minimize teratogenic effects to the fetus,
and utilize a multidisciplinary approach, involving medical oncology, surgical oncology,
radiation oncology, radiology, and a maternal fetal medicine specialist. In spite of this
consensus, there is not a standardized approach for treating cancer in women diagnosed during
pregnancy. Due to the relative infrequency of this situation in the oncologic setting, the aims of
this study were to determine how comfortable oncologists are discussing pregnancy issues
related to treatment, specifically termination and fetal risks, to determine what oncologists view
as their primary responsibilities in the management of a woman diagnosed with cancer during
pregnancy, and to identify the challenges oncologists face when treating a woman diagnosed
with cancer during pregnancy. An 18 question survey was developed and distributed to
oncologists at The Methodist Hospital and the Memorial Hermann Hospital system. The results
from 53 completed anonymous surveys showed that oncologists who have treated at least one
patient diagnosed with cancer during pregnancy are significantly more likely to be comfortable
treating this patient population (p<0.01). Thus, providing care to one patient within this
population may be sufficient to establish a level of comfort in providing clinic care to a patient
diagnosed with cancer during pregnancy. Providers appear to recognize that a multidisciplinary
approach is needed when treating this patient population, though have differing opinions
regarding whom of these providers has the highest practice responsibility to address pregnancyrelated topics, including termination of pregnancy and risk of teratogenic effects. Additionally,
many providers acknowledge that barriers exist which create added challenges when treating
this patient population.
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Background
Cancer during pregnancy is occurring more often than in the past, as women are
delaying childbearing until later in life. Cancer is diagnosed in approximately 1/1000
pregnancies, with the most common cancers seen during pregnancy being breast cancer, cervical
cancer, Hodgkin and Non-Hodgkin lymphoma, leukemias, and melanoma (1). The National
Comprehensive Cancer Network (NCCN) published guidelines for treatment of breast cancer
during pregnancy in 2006 (2). For additional cancers, a consensus exists that management
should prioritize survival of the mother while minimizing teratogenic effects to the fetus (3); it
is further suggested that a multidisciplinary approach be used, involving medical, surgical, and
radiation oncology, radiology, and a maternal fetal medicine specialist (MFM) (4). In spite of
this consensus, there is not a standardized approach for treating cancer in patients diagnosed
during pregnancy.
Breast cancer is the most common cancer diagnosed in women, and the most common
diagnosis during pregnancy. It is estimated to occur in 1/1500-1/4000 pregnancies, and
approximately 10% of breast cancer patients younger than age 40 are diagnosed during
pregnancy or up to one year postpartum (5, 6, 7). Several factors delay diagnosis, including
physiological changes in the breast during pregnancy, making the diagnosis of advanced stage
disease a common occurrence (8, 9). Breast surgery is safe during pregnancy, but a general
agreement exists to postpone radiation therapy and endocrine therapy until the postpartum
period, as both have been associated with a high risk of fetal toxicity (6, 10, 11). The young age
at which pregnant women are diagnosed with breast cancer puts them at an increased likelihood
of carrying a BRCA1 or BRCA2 mutation. In these instances, genetic testing for hereditary
breast and ovarian cancer syndrome should be considered (12).
Additional cancers more commonly seen in pregnancy include cervical cancer,
hematologic malignancies, leukemias, and melanoma. These diagnoses occur during pregnancy
at rates from 1/6000 to 1/100000, with lymphomas being the most common, and melanoma
being the most likely malignancy to metastasize to the placenta and fetus (3, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22). Treatment approaches for each of these cancers during pregnancy should be
individualized depending on disease staging, gestational age, and treatment options.
When faced with a cancer diagnosis during pregnancy, a multidisciplinary approach is
recommended, which may include oncologic specialties, surgery, and high risk obstetrics (9).
Cancer management is associated with potential teratogenic effects, including clinical use of
1

supportive agents, ionizing radiation exposure, and infection-related fever (23, 24). Risks of
fetal structural defects as a result of chemotherapy administration are greatest in the first
trimester, and radiation therapy should be delayed until after delivery. Given the limited data
regarding single-agent exposures, broad comparisons cannot be made to the risks associated
with combination therapies utilized during cancer treatment (24). Chemotherapy treatment is
thought to pose fewer risks when administered in the second and third trimesters, though
exposure during this time has been associated with transient neonatal disorders. While these
tend to resolve, the greatest concern associated with second and third trimester exposures is
harmful effects on fetal brain development (7).
While some information is available regarding potential approaches to cancer
management during pregnancy, outcome information is largely based on small numbers of case
series. Additionally, pregnant women are excluded from nearly all cancer trials and drug trials,
further preventing the establishment of clinical evidence to guide recommendations (11). In
current practice, oncologists rarely recommend termination of pregnancy, as the historical
practice of termination of pregnancy secondary to cancer has not been associated with improved
survival (11, 25, 26, 27). The diagnosis of an aggressive or advanced disease may be an
exception, as immediate treatment is needed to avoid patient mortality (11, 28, 29).
Consideration of whether to terminate pregnancy following a cancer diagnosis should be made
in the context of disease, agents and drugs to be used, probability of achieving a cure, and
patient desires (30).
As the incidence of cancer during pregnancy continues to rise, clinicians will
increasingly face challenges in managing cancer during pregnancy, particularly in developing a
treatment plan to maximize maternal benefits and minimize the risk of adverse pregnancy
outcomes (23). Studies in the past have tried to characterize approaches towards cancer during
pregnancy, but information remains limited. Additionally, information regarding the scope of
practice of oncologists in caring for a pregnant patient is scarce. A European study aimed to
evaluate provider opinions and knowledge surrounding the treatment possibilities for patients
with cancer in pregnancy and found that providers are uncertain regarding the timing and
approach towards treating cancer during pregnancy (31). In light of deficiencies in the amount
of information surrounding this topic in the oncologic setting, the goal of the current study was
to gain more insight into the perceived views of pregnancy management and challenges faced
by oncologists when treating women diagnosed with cancer during pregnancy.
2

Materials and Methods
A four-page survey was designed with 18 questions on oncologists’ opinions and
perceptions in the treatment of cancer during pregnancy (Appendix 1). The first section of the
survey assessed oncologists’ comfort level and experience with pregnant patients. The second
half of the survey inquired about the practice responsibilities and challenges of oncologists
when treating pregnant patients. Demographics, practice type, and self-reported number of
pregnant cancer patients seen were also examined. Human subject research approval was
obtained for the Methodist Hospital, the Memorial Hermann Health System, and the University
of Texas Health Science Center by the Institutional Review Board at each site. Both online and
paper survey data were collected beginning in October 2013, and ending in March 2014.
SurveyMonkey (http://www.surveymonkey.com) was utilized for email survey distribution and
data collection. Additionally, surveys were distributed during tumor board meetings at the
Houston Methodist Hospital system and the Memorial Hermann Health System. Participants
were not required to answer all questions; therefore, some answers have missing values.
Statistical analysis software, Stata (v.13.0, College Station, TX), was used to perform
standard descriptive analysis of categorical variables, including number of respondents and
percentages across categories. Kruskal-Wallis tests were used to compare differences in
comfort level by various predictor factors. Univariable and multivariable logistic regression
analyses were used to identify significant associations between respondents’ demographic
information, reported comfort level, perceived practice responsibilities, and barriers identified
which create challenges when treating this patient population. Statistical significance was
assumed at confidence intervals that did not include the null value (1.0) or at a p-value <0.05.
Results
Demographic Information
A total of 62 surveys were submitted: 5 surveys (8.1%) were excluded because all questions
regarding cancer during pregnancy were unanswered, with 4 (6.4%) excluded because the
survey was completed by an individual ineligible to participate in the study based on practice
area. This left a final sample size of 53 (85.5%) for analysis. Table 1 shows the demographic
data of the respondents. Most were medical oncologists (55.8%), with the remaining
respondents divided between radiation, surgical, and gynecologic oncology. Approximately
83% of respondents had treated at least one patient diagnosed with cancer during pregnancy
during their career, with 17% having no experience with this patient population.
3

Table 1. Participant Demographics
Institution (n=53)
Methodist
UT Memorial Hermann Hospital (UTMHH)
Survey Format (n=53)
Online
Paper
Gender (n=53)
Male
Female
Residency Completed (year) (n=53)
<1985
1985-1994
1995-2005
>2005
Years of Experience (n=53)
0-5 years
6-10 years
11-15 years
16-20 years
>20 years
Practice Area (n=52)
Medical Oncology
Surgical Oncology
Radiation Oncology
Gynecologic Oncology
Subspecialty (n=53)
Breast
GI
Hematology
Endocrine
Other
Not Applicable
Practice Setting (n=53)
Academic Hospital
Private Practice
Community Hospital
Cancer Center
Total Number of Pregnant Patients Seen
During Career Span (n=53)
None
1-5
>5

n
20
33
n
24
29
n
32
21
n
12
11
15
15
n
16
7
7
2
21
n
29
7
8
8
n
16
4
4
0
4
25
n
25
24
6
4

%
37.7
62.3
%
45.3
54.7
%
60.4
39.6
%
22.6
20.8
28.3
28.3
%
30.2
13.2
13.2
3.8
39.6
%
55.8
13.4
15.4
15.4
%
30.2
7.5
7.5
0.0
7.5
47.2
%
47.2
45.3
11.3
7.5

n

%

9
29
15

17.0
54.7
28.3
4

Oncologist Comfort Level
The comfort level of oncologists in treating patients diagnosed with cancer during pregnancy
was assessed using a 5-point Likert scale. Approximately 60% of respondents stated they were
comfortable/very comfortable in treating this patient population, with remaining respondents
being divided between feeling uncertain and uncomfortable/very uncomfortable. Comfort level
in discussing effects of treatment on pregnancy management and/or the fetus, and in discussing
prognosis, pregnancy options, and future considerations for the patient (Table 2) were assessed.
Overall, participants displayed consistency in their degree of comfort when discussing various
pregnancy-related topics with patients in regards to cancer management. At least 50% of
participants reported being comfortable/very comfortable in discussing pregnancy related topics,
with the discussion of long-term risks to the child being the exception (40%). Participants were
comfortable/very comfortable (52%) in the discussion of termination of pregnancy, with 17%
feeling uncertain, and 30% feeling uncomfortable/very uncomfortable.
Table 2. Responses to the question pertaining to comfort level in discussing the effects of
treatment
Very
Very
Uncomfortable Uncomfortable Uncertain Comfortable Comfortable
Answer Options
(%)
(%)
(%)
(%)
(%)
Risks of
9 (17.0)
5 (9.4)
6 (11.3)
19 (35.8)
14 (26.4)
Chemotherapy
Risk of
7 (13.2)
7 (13.2)
6 (11.3)
19 (35.8)
14 (26.4)
Teratogenic
Effects
Risks of Surgery
Risk of
treatmentrelated Birth
Defects

7 (13.2)

8 (15.1)

7 (13.2)

20 (37.7)

11 (20.8)

8 (15.1)

7 (13.2)

9 (17.0)

16 (30.2)

13 (24.5)

Risk of Delivery
Complications
Risks of
Radiation
Therapy

9 (17.0)

6 (11.3)

9 (17.0)

20(37.7)

9 (17.0)

8 (15.1)

6 (11.3)

12 (22.6)

14 (26.4)

13 (24.5)

Long-term Risks
to the child
Risk of
Transient fetal
conditions

8 (15.1)

7 (13.2)

16 (30.2)

11 (20.8)

11 (20.8)

7 (13.2)

7 (13.2)

18 (34.0)

9 (17.0)

12 (22.6)
5

Table 3. Responses to the question pertaining to comfort level in discussing prognosis,
pregnancy options, and future considerations
Very
Very
Uncomfortable Uncomfortable Uncertain Comfortable Comfortable
Answer Options
(%)
(%)
(%)
(%)
(%)
Prognosis and
effect of
7 (13.2)
4 (7.5)
9 (17.0)
18 (34.0)
15 (28.3)
pregnancy on
prognosis
Timing of
Delivery with
7 (13.2)
7 (13.2)
8 (15.1)
19 (35.8)
12 (22.6)
respect to the
treatment plan
Implications for
Future Fertility
Risk of cancer
Metastasis

6 (11.3)

5 (9.4)

11 (20.8)

15 (28.3)

16 (30.2)

8 (15.1)

5 (9.4)

10 (18.9)

17 (32.1)

13 (24.5)

Implications for
Breast Feeding
Termination of
pregnancy

5 (9.4)

6 (11.3)

13 (24.5)

16 (30.2)

13 (24.5)

7 (13.2)

9 (17.0)

9 (17.0)

16 (30.2)

12 (22.6)

Oncologist Practice Responsibilities
The practice responsibilities of oncologists in managing women diagnosed with cancer during
pregnancy were examined. Participants were questioned on whom they believe should be
involved in the care of a patient diagnosed with cancer during pregnancy. They were
additionally asked who has the highest responsibility to discuss termination of pregnancy and
teratogenic risks to the fetus with the patient, and to rank sources they would refer to for
information pertaining to teratogenic effects of cancer treatments during pregnancy (Table 4).
MFM’s and medical oncologists ranked highly across all questioning. Genetic counselors and
surgical oncologists were ranked as having low responsibility to discuss termination of
pregnancy and teratogenic risks to the fetus. In examining sources of reference for information
pertaining to teratogenic effects of cancer treatment, MFM’s ranked highest, with Ob/Gyns and
a search engine such as PubMed ranking lowest as sources of information participants would
reference.
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Table 4. Patient management and practice responsibility
Health Care Provider

Responsibility to
discuss termination
of pregnancy as a
treatment option

Medical Oncologist n=44
MFM n=40
Ob/Gyn n=40
Genetic Counselor n=35
Surgical Oncologist n=35
Other n=1
Health Care Provider

Responsibility to
discuss the
teratogenic risks to
the fetus related to
cancer treatment
options

Medical Oncologist n=45
MFM n=40
Ob/Gyn n=36
Radiation Oncologist n=36
Genetic Counselor n=36
Surgical Oncologist n=35
Other n=3
Health Care Provider

Sources of reference
for information
pertaining to
teratogenic effects of
cancer treatments
during pregnancy

MFM n=42
Oncologist Colleague n=45
Genetic Counselor n=36
Teratogen Helpline n=35
Ob/Gyn n=32
PubMed n=32

Responsibility Rank
High (%)
Mid (%)
Low (%)
30 (68.2)
10 (22.7)
4 (9.1)
27 (67.5)
11 (27.5)
2 (5.0)
26 (65.0)
11 (27.5)
3 (7.5)
5 (14.3)
13 (37.1)
17 (48.6)
1 (2.9)
23 (65.7)
11 (31.4)
1 (100.0)
0 (0.0)
0 (0.0)
Responsibility Rank
High (%)
Mid (%)
Low (%)
36 (80%)
7 (15.6)
2 (4.4)
23 (57.5)
12 (30.0)
5 (12.5)
16 (44.4)
12 (33.3)
8 (22.2)
9 (25.0)
22 (61.1)
5 (13.9)
6 (16.7)
10 (27.8)
20 (55.6)
4 (11.4)
8 (22.9)
23 (65.7)
3 (100.0)
0 (0.0)
0 (0.0)
Reference Rank
High (%)
Mid (%)
31 (73.8)
11 (26.2)
28 (62.2)
9 (20.0)
11 (30.5)
14 (38.9)
11 (31.4)
13 (37.1)
8 (25.0)
17 (53.1)
7 (21.9)
10 (31.2)

Low (%)
0 (0.0)
8 (17.8)
11 (30.5)
11 (31.4)
7 (21.9)
15 (46.9)

Challenges
Participants were lastly asked to identify barriers which they felt created challenges when
treating a patient diagnosed with cancer during pregnancy (Table 5). Approximately 20% of
participants wrote-in additional barriers which they felt create challenges (Appendix 2).
Approximately 80% of all respondents felt that there was at least one barrier, with most
reporting more than one barrier. Of these, 83% had experience treating at least one pregnant
patient in their career. Of those reporting no barriers, only one respondent (16%) had no
experience treating pregnant patients in their career. Those who felt there were other challenges
were primarily comfortable in treating patients diagnosed during pregnancy.
7

Table 5. Barriers which create challenges in managing patients diagnosed with cancer during
pregnancy
Disagree
Answer Options
Agree (%)
(%)
34 (64.2)
19 (35.8)
Lack of prevalence of this patient population creates barriers
31 (58.5)
22 (41.5)
Knowledge of safe treatment options creates barriers
29 (54.7)
24 (45.3)
Lack of standardization of care creates barriers
28 (52.8)
25 (47.2)
Amount of information available for reference creates barriers
11 (20.8)
42 (79.2)
There are no barriers
11 (20.8)
42 (79.2)
Other challenges create barriers
Statistically significant differences in comfort level were observed separately for gender,
survey format, and institution; however, multivariable ordinal logistic regression analysis
demonstrated that when controlling for experience with the patient population, the differences
seen between institutions was found to be non-significant (p=0.072). Additionally, when
controlling for the institution demographic, the differences seen between gender (p=0.665) and
survey format (p=0.230) were found to be non-significant.
Associations between participant experience with patients diagnosed during pregnancy
and comfort level in treating pregnant patients was assessed: participants who had treated at
least one patient diagnosed during pregnancy were significantly more likely to feel comfortable
when treating pregnant patients (p<0.01) (Figure 1).
Figure 1. Reported comfort level in treating a patient diagnosed during pregnancy based on
experience with this patient population (p<0.01)
100%
Pregnant
Patients
Treated
over Span
of Career
>5

80%
60%
40%

1-5
20%

None

0%
Very
Uncomfortable
Uncomfortable

Uncertain

Comfortable

Very
Comfortable

Comfort Level
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The comfort level of oncologists in discussing pregnancy-related topics associated with
cancer treatment was also assessed. Pair-wise correlation analysis demonstrated that the topics
assessed in Tables 2 and 3 were highly correlated with one another (at least 60%), with
approximately 55% demonstrating greater than 80% correlation. Thus, if a participant was
comfortable with one pregnancy-related topic, they were significantly more likely to be
comfortable with all topics (p<0.001). Overall, participants reported they are comfortable
treating patients diagnosed with cancer during pregnancy and discussing pregnancy topics
related to cancer treatment.
The oncologic sub-specialty of participants influenced comfort levels, with surgical and
radiation oncologists significantly more likely to be uncomfortable with certain topics when
compared to medical and gynecologic oncologists. These topics included discussing risks of
surgery (p<0.01), risks of chemotherapy (p<0.01), risk of treatment-related birth defects
(p<0.05), risk of transient neonatal conditions (p<0.05), risk of delivery complications (p<0.05),
risk of cancer metastasis (p<0.05), termination of pregnancy (p<0.05), timing of delivery with
respect to the treatment plan (p<0.01), and implications for breast feeding (p<0.05). Participants
who were uncomfortable discussing the following were significantly more likely to rank a
genetic counselor as being a high reference for information pertaining to teratogenic effects of
cancer treatments (p<0.05): risks of surgery, risk of treatment-related birth defects, risk of
transient neonatal conditions, long-term risks to the child, prognosis and the effect of pregnancy
on prognosis, timing of delivery with respect to the treatment plan, risk of cancer metastasis,
and implications for breast feeding. Oncologist colleagues and MFM’s were consistently
ranked highly for reference regarding teratogens; however this was not found to be statistically
significant when compared with overall comfort in treating, or when examined for comfort level
across all pregnancy-related discussion topics.
Participants who felt uncomfortable discussing pregnancy-related topics were
significantly more likely to rank Ob/Gyns as having high responsibility to discuss termination of
pregnancy (p<0.05). However, participants who practice gynecologic oncology were
significantly more likely to think an Ob/Gyn does not need to be involved in the care of a
patient diagnosed with cancer during pregnancy (p<0.01). Participants who felt uncomfortable
discussing risks of teratogenic effects and risk of metastasis were significantly more likely to
rank medical oncologists as having high responsibility to discuss teratogenic risks to the fetus
(p<0.05). Lastly, those who ranked genetic counselors as having high responsibility to discuss
9

teratogens were significantly more likely to be uncomfortable treating patients diagnosed with
cancer during pregnancy (p<0.01).
Those participants who that felt there were no barriers when treating this patient
population were examined for comfort level when treating a patient diagnosed with cancer
during pregnancy, but this was not found to be statistically significant (p>0.1).
Discussion
The goal of this study was to identify the perceived views of pregnancy management and
challenges faced by oncologists when treating women diagnosed with cancer during pregnancy.
Few studies have specifically examined oncologist comfort level, though one demonstrated
oncologist discomfort in utilization of psychosocial talk in comparison with nurses and
physician assistants (32). To the best of current knowledge, this is the first study to assess the
comfort level of oncologists in regards to cancer diagnosis during pregnancy. Given that 1/1000
pregnancies are diagnosed with cancer, it was thought oncologists would be uncomfortable
discussing pregnancy recommendations. This study found the majority of participants had
treated at least one patient diagnosed with cancer during pregnancy (83%), and participants with
limited experience (1-5 patients) reported a greater level of comfort treating these patients
compared to those with no experience (0 patients). Those who had treated more than 5 patients
diagnosed with cancer during pregnancy were significantly more likely to feel comfortable
when treating this patient population compared to those with less experience (p<0.01). While
the sample population was skewed due to the tertiary care environment of the institutions
involved in this study, it appears that treating a few patients diagnosed with cancer during
pregnancy may be sufficient for a provider to feel comfortable treating this patient population
overall.
Comfort level in discussing termination of pregnancy was the only topic assessed that
did not have a significant association with comfort level overall in treating this patient
population (p=0.08). Thus, provider comfort level in treating a patient diagnosed with cancer
during pregnancy cannot be used as a predictor for comfort in discussing termination of
pregnancy. Because participants tended to be less comfortable discussing termination of
pregnancy, this may explain the high ranking of MFM’s in regards to practice responsibility to
discuss termination. However, many other factors influence comfort level in discussing
termination aside from training and whether it traditionally falls within a provider’s scope of
practice. For instance, overall personal beliefs and feelings are likely to influence comfort level.
10

The findings of this study suggest medical oncologists and MFM’s have a significant
role in the management of this patient population. Genetic counselors were consistently ranked
as having low responsibility to discuss pregnancy-related topics with patients. This study did not
assess awareness of the practice competencies of genetic counselors, nor did it assess whether
participants routinely work with a genetic counselor. Additionally, the distinction between
different genetic counseling specialties was not taken into account. Participant responses may
reflect that they feel a cancer genetic counselor has low responsibility to discuss these topics,
but they may feel a prenatal genetic counselor has higher responsibility.
While the diagnosis of cancer during pregnancy more prevalent now than in the past,
particularly as women continue to delay childbearing, barriers which create challenges when
treating this patient population continue to exist. NCCN guidelines for the clinical management
of women diagnosed with breast cancer during pregnancy were published in 2006 (2), but
similar guidelines for additional cancers have not yet been established. Participants identified
the lack of standardization of care as a barrier which creates challenges in the management of
pregnant patients. Thus, the creation of guidelines for the treatment of other cancers during
pregnancy may decrease the barriers perceived by providers, and potentially contribute to
overall comfort when treating this patient population.
There were limitations to this study, first in the number of providers included in the
study. Surveying a wider variety and larger number of providers may provide further insights to
the clinical management of women diagnosed with cancer during pregnancy. The two
institutions utilized in the study are in a tertiary care environment, with participants being more
likely to have experience with pregnant patients than oncologists in the general setting.
Therefore, it may be difficult to generalize the findings of this study across the field of
oncology. Additionally, a large proportion of study participants subspecialize in the treatment
of breast cancer, the only cancer for which standardized guidelines for treatment exist, creating
a potential respondent bias.
In spite of limitations, the findings of this study provide a platform for future studies,
which may include assessing provider knowledge and gathering opinions in regards to treatment
approach, and in assessing the involvement of genetic counseling and genetic testing. Given the
high ranking of MFM’s in regards to practice responsibilities, the survey in this study could be
administered to MFM’s to assess whether trends in MFM comfort level reflect those
demonstrated by oncologists. In addition, a study examining the knowledge of providers in
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regards to the scope of practice of genetic counselors may provide additional insights regarding
the importance of genetics when considering a cancer diagnosis during pregnancy.
In conclusion, the findings of this study suggest that experience with women diagnosed
with cancer during pregnancy is directly related to comfort level in treating this patient
population; providing care to a few pregnant patients may be sufficient to establish a level of
comfort in an oncologist when treating pregnant patients. Oncologists recognize that a
multidisciplinary approach is needed when treating this patient population, though have
differing opinions regarding whom of these providers has the highest practice responsibility to
address pregnancy-related topics. Additionally, comfort level and experience aside, oncologists
acknowledge that barriers exist which create challenges when treating pregnant patients.
Minimization of these barriers may contribute towards further increasing comfort level when
treating a woman diagnosed with cancer during pregnancy.
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Appendix
Appendix 1. Study Survey
Part I (Demographics)
1) What is your gender?
 Male
 Female
2) What year did you complete your primary residency?
_________ (year)
3) What year did you complete your fellowship and/or sub-specialty training?
Select all that apply:
 Fellowship: _________(year)
 Sub-specialty: _________ (year)
 Not Applicable
4) How many years have you been in practice?
Please choose one:
 0-5 years
 6-10 years
 11-15 years
 16-20 years
 >20 years
5) Which of the following best describes your area of practice?
Please choose one:
 Medical Oncology
 Surgical Oncology
 Radiation Oncology
 Gynecologic Oncology
6) Which of the following best describes your sub-specialty?
Please choose one:
 Breast
 GI
 Hematology
 Endocrine
 Other:____________________________
 Not Applicable
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7) What is your primary practice setting?
Please select all that apply:
 Academic Hospital
 Private Practice
 Community Hospital
 Cancer Center
 Other: ___________________________
8) On average, how many new patients in each setting below do you see each week?
Inpatient: ____________ (number per week)
Outpatient: __________ (number per week)

Part II (comfort level/experience)
1) In the span of your career, how many patients have you treated who were undergoing active
treatment for cancer during pregnancy?
Please choose one:
 None
 1-5
 6-10
 11-15
 >15 Please specify approximately how many: ______
2) How comfortable do you feel treating a patient diagnosed with cancer during pregnancy?


Very
Uncomfortable (2)
Uncomfortable (1)


Uncertain (3)


Comfortable (4)


Very
Comfortable (5)

3) How comfortable would you feel discussing the following with a patient diagnosed with
any cancer during pregnancy? Please indicate your answer choice by marking the
appropriate column below:
1= Very Uncomfortable; 2=Uncomfortable; 3=Uncertain; 4=Comfortable; 5=Very Comfortable
Discussing Effects of Treatment
Safety and fetal risks of surgery during pregnancy.
Safety and fetal risks of radiation therapy administration during pregnancy.
Safety and fetal risk of chemotherapy administration during pregnancy.
Risk of teratogenic effects from cancer treatment during pregnancy.
Risk of birth defects related to treatment.
Risk of transient fetal conditions related to treatment.
Long-term risk to the child following treatment during pregnancy.
Risk of delivery complications related to cancer treatment.

1

2

3

4

5
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4) How comfortable would you feel discussing the following with a patient diagnosed with
any cancer during pregnancy? Please indicate your answer choice by marking the
appropriate column below:
1= Very Uncomfortable; 2=Uncomfortable; 3=Uncertain; 4=Comfortable; 5=Very Comfortable
Discussing Prognosis, Pregnancy Options, and Future Considerations
Prognosis and whether continuation of pregnancy affects the prognosis.
Risk of cancer metastasis to the fetus and/or placenta.
Discussing termination of pregnancy.
How timing of delivery fits into the treatment plan.
Implications for breast feeding.
Implications for future fertility.

1

2

3

4

5

Please respond to the remainder of the survey according to one of the
following:
I do not have experience treating a patient diagnosed with cancer during pregnancy. The
following reflects how I think I would approach this type of case.
OR
I do have experience treating a patient diagnosed with cancer during pregnancy. The following
reflects how I approach this type of case.

Part III (practice responsibilities/challenges)
1) Do you agree or disagree with the following statements? Please indicate your answer
choice by marking the appropriate column below.
Agree

Disagree

Your management of a patient would change if she was pregnant at the time
of diagnosis.
It is one of your practice responsibilities to address pregnancy management
with patients diagnosed with cancer during pregnancy.
It is one of your practice responsibilities to make appropriate referrals for
pregnancy management during cancer treatment.
You know which specialists should be following your patient while she is
being treated during pregnancy, and would feel comfortable making
those referrals.
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2) Who do you think should be involved in the care of a patient diagnosed with cancer during
pregnancy?
Please select all that apply:
 Medical Oncology
 Surgical Oncology
 Radiation Oncology
 OB/GYN
 MFM
 Genetic Counselor
 Other: ___________________________________
 Not sure
3) Please rank the following accordingly: Who do you feel has the primary responsibility of
discussing termination of pregnancy as a treatment option with the patient?
1=highest responsibility; 6 = lowest responsibility
_______ Medical Oncologist
_______ Surgical Oncologist
_______ OB/GYN
_______ MFM
_______ Genetic Counselor
_______ Other: _____________________________________
4) Please rank the following accordingly: Who do you feel has the primary responsibility of
discussing the teratogenic risks to the fetus related to cancer treatment options?
1=highest responsibility; 7 = lowest responsibility
_______ Medical Oncologist
_______ Surgical Oncologist
_______ Radiation Oncologist
_______ OB/GYN
_______ MFM
_______ Genetic Counselor
_______ Other: _____________________________________
5) Please rank the following accordingly: Who/What would you refer to for information
pertaining to teratogenic effects of cancer treatments during pregnancy, regardless of type of
treatment?
1=refer to first; 2=refer to second; 3=refer to third, etc.
_______ Oncologist Colleague
_______ MFM
_______ Ob/Gyn
_______ Genetic Counselor
_______ PubMed
_______ Teratogen helpline/Teratogen information service
_______ Other: _____________________________________
16

6) What barriers do you feel create challenges when treating a patient diagnosed with cancer
during pregnancy? Please mark all that apply:
 Amount of information available for reference
 Knowledge of safe treatment options
 Lack of prevalence of this patient population
 Lack of standardization of care for this patient population
 I do not feel that there are any barriers
 Other, please describe:
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
____________________________________________

You have reached the end of the survey. Thank you for your time.
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Appendix 2. Responses to part III, question 6 of the survey: Other barriers identified that create
challenges when treating a patient diagnosed with cancer during pregnancy:
 Discussion of termination of pregnancy as an option
 No experience; refer to tertiary center
 Fear of litigation
 The obvious emotional component AND the stage of the patient, whether curable or
whether already metastatic
 Pregnancy and cancer is a very difficult subject especially when radiation therapy had
potentially devastating effects to a developing fetus. I also find people’s religious views
have a great barrier when decision making. Also the current political climate regarding
abortion makes it difficult.
 A team effort is needed Although the above questions asked for a rank order--I believe
the decision should be made with all team members mentioned above being involved
Just the medical oncologist alone or MFM alone will not be able to make the right
decision Each team member has a different expertise and different information to offer
that can be utilized in decision making MFM and OBGYN and genetic counselor should
be actively involved in decision making along with the various oncology colleagues The
clinical pharmacist plays a very vital role here and needs to be involved in the decision
making Reproductive Endocrinology can be another valuable team member to be
involved here who can help address current as well as future issues,
 Historical reports about poor prognosis associated with pregnancy and cancer
 We routinely perform procedures with patients who are pregnant with and without
cancer. We modify our procedures by using different medication for sedation to
minimize radiation use, particularly in the first and second trimesters
 I think that the best data for management of breast cancer is out of MDACC in
pregnancy; otherwise, data is scarce. However we do have the experience which is in
fact well published.
 Concern for being sued if the fetus has any adverse effects.
 Rare.
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